Parkinsonism is not a single disease. It’s a clinical syndrome, an umbrella term for a group of movement problems that share four core features: slowness of movement, tremor, muscle stiffness, and difficulty with balance. Parkinson’s disease is the most common cause of parkinsonism, but it’s only one of many. Several other brain conditions, certain medications, toxic exposures, and even stroke damage can produce the same set of symptoms.
Understanding the distinction matters because the cause behind someone’s parkinsonism shapes how well they respond to treatment, how quickly symptoms progress, and what to expect over time.
The Four Core Symptoms
Regardless of the underlying cause, parkinsonism is defined by a specific cluster of motor problems. Bradykinesia, or slowness of movement, is the hallmark. It shows up as smaller handwriting, softer speech, reduced facial expression, and a general feeling that everyday movements take more effort and time. Simple tasks like buttoning a shirt or stirring a pot become noticeably harder.
Tremor in parkinsonism typically occurs at rest, meaning your hand shakes while it’s sitting in your lap but may calm down when you reach for something. This distinguishes it from the tremor in essential tremor, which usually worsens with action. The tremor frequency in parkinsonism generally falls between 3.5 and 7.5 cycles per second.
Rigidity is a constant stiffness in the muscles that others can feel when they try to move your arm or leg. It’s different from the spasticity that follows a stroke. Postural instability, the fourth feature, refers to impaired balance reflexes. People with parkinsonism may find themselves tipping forward or backward without being able to catch themselves, leading to falls.
Parkinsonism vs. Parkinson’s Disease
Parkinson’s disease accounts for the majority of parkinsonism cases. It results from the gradual loss of brain cells that produce dopamine, a chemical messenger essential for smooth, coordinated movement. These dying cells also develop abnormal protein clumps called Lewy bodies. The disease tends to start on one side of the body, progresses slowly over years or even decades, and responds well to dopamine-replacement medication.
Global estimates from 2019 put the number of people living with Parkinson’s disease at over 8.5 million, and that figure has doubled in the past 25 years according to the World Health Organization. But the broader category of parkinsonism includes several other conditions that look similar at first glance yet behave very differently.
Atypical Parkinsonian Syndromes
When parkinsonism is caused by a neurodegenerative disease other than Parkinson’s, doctors call it atypical parkinsonism or a “Parkinson-plus” syndrome. These conditions tend to progress faster, respond poorly to standard medications, and produce additional neurological problems that Parkinson’s disease typically does not.
Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) stands out for causing early, unexplained falls and difficulty moving the eyes, particularly looking up or down. People with PSP often develop balance problems and fall backward within the first year or two, while someone with Parkinson’s disease may not have significant balance trouble for a decade. Stiffness tends to concentrate in the trunk and neck rather than the limbs, and cognitive decline with slowed thinking is common early on.
Multiple System Atrophy
Multiple system atrophy (MSA) comes in two main forms. One looks like Parkinson’s disease with slowness and stiffness, but the symptoms are more symmetrical from the start and the tremor is often atypical. The other form primarily affects coordination, causing unsteady walking, clumsy limbs, and slurred speech. Both forms share a hallmark feature: early and severe problems with the body’s automatic functions, including dramatic drops in blood pressure upon standing, bladder dysfunction, and sleep disturbances. These autonomic symptoms can even appear months to years before any movement problems.
Corticobasal Degeneration
Corticobasal degeneration (CBD) is the rarest of the three and is notable for strikingly lopsided symptoms. It usually begins with clumsiness or loss of skilled movement in one hand. Someone might find they can no longer use a tool or perform a familiar gesture, not because of weakness but because the brain has lost the ability to plan the movement. Muscle jerks, stiffness, and a slow cognitive decline follow.
Secondary Causes of Parkinsonism
Not all parkinsonism comes from a degenerating brain. Secondary parkinsonism has an identifiable external trigger, and in some cases the symptoms can be partially or fully reversed.
Drug-Induced Parkinsonism
Medications are one of the most common secondary causes. Older antipsychotic drugs like haloperidol are the biggest offenders, but newer antipsychotics including risperidone and olanzapine can also be responsible. Outside of psychiatry, stomach-motility drugs like metoclopramide (often prescribed for nausea) are a frequent culprit. Certain calcium channel blockers used for dizziness and headache, the seizure medication valproic acid (which causes parkinsonism in about 5% of long-term users), and lithium have all been linked to drug-induced parkinsonism. In many cases, symptoms improve or resolve after the offending medication is stopped, though recovery can take weeks to months.
Vascular Parkinsonism
Strokes or chronic damage to the small blood vessels deep in the brain can produce parkinsonism that looks distinct from Parkinson’s disease. Vascular parkinsonism classically affects the lower body: walking becomes shuffling and unsteady, feet may freeze to the floor, and balance is poor, but the hands are often relatively spared and resting tremor is usually absent. The stance tends to be wider than in Parkinson’s disease, and there are often additional signs of stroke damage like exaggerated reflexes. Onset can be sudden after a stroke or creep in gradually as small-vessel disease accumulates.
Toxin Exposure
Certain environmental exposures can damage the dopamine system directly. High-dose manganese exposure, seen in some welders and industrial workers, causes a form of parkinsonism called manganism. Pesticides including rotenone and the herbicide paraquat have been linked to increased risk. The synthetic compound MPTP, discovered in the 1980s when contaminated street drugs caused sudden parkinsonism in young people, remains one of the clearest examples of a toxin that destroys dopamine-producing cells. Solvents like trichloroethylene (used in metal degreasing and dry cleaning) and organic pollutants like PCBs have also been associated with parkinsonism, with researchers finding elevated PCB concentrations in the brains of affected individuals.
How Doctors Tell the Difference
Distinguishing Parkinson’s disease from other forms of parkinsonism is one of the most important steps in diagnosis, because it determines treatment and prognosis. The process starts with a detailed neurological exam. Doctors look for clues: Did symptoms start on one side or both? Were falls an early problem or a late one? Are there eye movement abnormalities, severe blood pressure drops, or signs of stroke?
When the exam alone isn’t conclusive, a specialized brain scan called a DaTscan can help. This imaging test measures the activity of dopamine-transporting cells in the brain. It’s the only imaging technique approved in both the United States and the European Union for distinguishing Parkinson’s disease and other forms of degenerative parkinsonism from conditions like essential tremor or drug-induced parkinsonism, where the dopamine system is intact. An abnormal DaTscan confirms that dopamine cells are being lost, but it cannot distinguish Parkinson’s disease from the atypical syndromes, since all of them can damage the dopamine system.
Standard MRI scans can reveal vascular damage pointing to vascular parkinsonism, or specific brain atrophy patterns that suggest PSP or MSA. Often, the most telling diagnostic tool is time. How someone’s symptoms evolve over months and years reveals patterns that may not be clear at the first visit.
Treatment Response Varies by Type
Parkinson’s disease responds well to dopamine-replacement therapy. This strong medication response is actually considered a key supporting feature when confirming a Parkinson’s diagnosis. People with Parkinson’s disease often experience significant improvement in slowness, stiffness, and tremor.
The picture is very different in atypical parkinsonism. In clinical testing of patients with MSA, about 77% showed no change in their overall motor scores after receiving dopamine-replacement medication. Among those who did respond, improvements were limited and selective: action tremor improved in about 35% of MSA patients, while stiffness and resting tremor showed modest improvement in roughly 15%. PSP patients occasionally see small reductions in slowness and rigidity, but the improvements are rarely clinically meaningful. A small subset of people with atypical parkinsonism do get some benefit, so a trial of medication is still worthwhile, but the muted response itself becomes a diagnostic clue.
For drug-induced parkinsonism, the primary treatment is discontinuing or switching the responsible medication when possible. In vascular parkinsonism, managing the underlying vascular risk factors (blood pressure, cholesterol, blood sugar) is central, though dopamine-replacement medication typically provides little benefit. Across all types, physical therapy, occupational therapy, and fall-prevention strategies play an important role in maintaining mobility and independence.
How Quickly Symptoms Progress
Progression speed is one of the starkest differences between types of parkinsonism. Parkinson’s disease is generally slow. Moving from early, mild symptoms to significant disability can take anywhere from a few years to decades, and lifestyle factors like exercise appear to have a meaningful impact on the timeline.
Atypical parkinsonian syndromes move considerably faster. MSA and PSP typically progress over 5 to 10 years, with disability accumulating more rapidly and fewer treatment options to slow things down. Early cognitive decline alongside parkinsonism may point to dementia with Lewy bodies, a related condition where thinking problems and movement symptoms develop in close proximity rather than years apart. Recognizing which type of parkinsonism someone has gives patients and families a clearer sense of what lies ahead and helps guide decisions about care and planning.